 |
|
|
| |
All-Oral Combination of Daclatasvir Plus Asunaprevir in Interferon-Ineligible Naïve/Intolerant and Nonresponder Japanese Patients Chronically Infected With HCV Genotype 1b: Results From a Phase 3 Trial
|
| |
| |
Reported by Jules Levin
AASLD 2013 Nov 1-4 Wash DC
Chayama K,1 Suzuki Y,2 Ikeda K,2 Toyota J,3 Karino Y,3 Kawakami Y,1 Ido A,4 Yamamoto K,5 Takaguchi K,6 Izumi N,7 Koike K,8 Takehara T,9 Kawada N,10 Sata M,11 Miyagoshi H,12 Eley T,13 McPhee F,13 Wenhua Hu,13 Ishikawa H,12 Hughes E,13 Kumada H2
1Hiroshima University, Hiroshima, Japan; 2Toranomon Hospital, Tokyo, Japan; 3Sapporo-Kousei General Hospital, Sapporo, Japan; 4Kagoshima University, Kagoshima, Japan; 5Okayama University, Okayama, Japan; 6Kagawa
Prefectural Hospital, Kagawa, Japan; 7Musashino Red Cross Hospital, Tokyo, Japan; 8University of Tokyo, Tokyo, Japan; 9Osaka University, Osaka, Japan; 10Osaka City University, Osaka, Japan; 11Kurume University, Fukuoka,
Japan; 12Bristol-Myers KK, Tokyo, Japan; 13Bristol-Myers Squibb Research & Development, Princeton, NJ, USA
|
| |
|
|
|
|
|
